scanance.
Sign inGet Premium
HI

Hims & Hers Health, Inc.

HIMSHealthcareNASDAQ

Drug Manufacturers - Specialty & Generic · Last scanned Jun 1, 2026

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$2.35B
+59.0% YoY
Net Income
$128.4M
+1.8% YoY
EBITDA
$160.1M
+102.7% YoY
Free Cash Flow
$174.3M

Scan Results

Daily timeframe
DateIndicatorDetails
Loading...
About Hims & Hers Health, Inc.

Headquartered within the healthcare sector, Hims & Hers Health, Inc. focuses on Drug Manufacturers - Specialty & Generic services and products. Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of. At a $6.05B market cap, Hims & Hers Health, Inc. ranks as a mid-cap company within healthcare. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.

Key stats
Market Cap$6.05B
Fwd P/E20.32
EPS$-0.09
Beta2.42
52W Change-53.9%
ROE-2.7%
Analysis

On the balance sheet, HIMS has $750.9M in cash with $1.13B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Annual free cash flow of $174.3M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of -2.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 0.6% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $526.9M (2022) to $2.35B (2025), reflecting a 346% increase over the period.

A beta of 2.42 means HIMS is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Hims & Hers Health, Inc.'s trajectory.

Links
Not financial advice. Scanance is an educational tool. Past performance does not guarantee future results.PrivacyTerms